Thermo Fisher Scientific Inc. (TMO)

210.61
0.11 0.05
NYSE : Health Technology
Prev Close 210.72
Open 210.26
Day Low/High 209.35 / 212.69
52 Wk Low/High 151.74 / 226.44
Volume 895.81K
Avg Volume 1.59M
Exchange NYSE
Shares Outstanding 401.00M
Market Cap 82.01B
EPS 5.60
P/E Ratio 35.78
Div & Yield 0.68 (0.29%)

Latest News

Big Pharma and the Sellers of Its Products Now Have a Problem

Big Pharma and the Sellers of Its Products Now Have a Problem

Who, out there in the health care sector, is safe?

Jim's Daily Rundown

Jim discusses GE, Comcast, Illinois Tool Works, and Abbott Labs, all of which reported earnings Wednesday morning.

Jim's Daily Rundown

In today's video, Jim discusses the government shutdown, an Eli Lilly downgrade, Schlumberger after Friday's earnings, and several other market-related topics.

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

It's hard to understand the magnitude of the change.

The New #181 Most Shorted S&P 500 Component: Thermo Fisher Scientific

The New #181 Most Shorted S&P 500 Component: Thermo Fisher Scientific

The most recent short interest data has been released for the 12/29/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Jim's Daily Rundown

In today's video, Jim discusses our newest initiation in Constellation Brands, Danaher at the JP Morgan Healthcare conference, and energy stocks.

Cramer: Lessons From the Market and ICR

Cramer: Lessons From the Market and ICR

You can make a case to buy any of the stocks of the companies at ICR.

Thermo Fisher Scientific Moves Up In Analyst Rankings, Passing Salesforce.com

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Thermo Fisher Scientific Inc has taken over the #14 spot from Salesforce. om Inc , according to ETF Channel.

Six Off the Beaten Path Healthcare Stock Gems

Six Off the Beaten Path Healthcare Stock Gems

These lesser-known diagnostic and life sciences firms are involved in areas from genetic tools to telemedicine.

Amazon Could Gain 20% by Entering Health Care

Amazon Could Gain 20% by Entering Health Care

Moving into higher-margin products could boost Amazon's gross margins by 1,000 basis points, one analyst contends.

The Real Story Is Not Tax Reform; It Is Global Demand: Market Recon

The Real Story Is Not Tax Reform; It Is Global Demand: Market Recon

It looks like China is building again.

Cramer: Here Are the Ideal Stocks Now

Cramer: Here Are the Ideal Stocks Now

All the great stocks have artificial intelligence and e-commerce in common.

Winners Of 2017 Nobel Prize In Chemistry Helped Spark "New Era" In Biochemistry

Winners Of 2017 Nobel Prize In Chemistry Helped Spark "New Era" In Biochemistry

Cryo-electron microscopes are used to "see the molecules inside the cell and how they interact"

First FDA-Approved Cell Therapy For Leukemia Utilizes Thermo Fisher Scientific's CTS Dynabeads Technology

First FDA-Approved Cell Therapy For Leukemia Utilizes Thermo Fisher Scientific's CTS Dynabeads Technology

Kymriah™ (tisagenlecleucel, formerly CTL019), the first FDA-approved CAR-T cell therapy, uses CTS Dynabeads CD3/CD28 spherical beads to isolate, activate and expand T cells

Thermo Fisher Scientific Announces Receipt Of All Required Regulatory Approvals For Proposed Acquisition Of Patheon

Thermo Fisher Scientific Announces Receipt Of All Required Regulatory Approvals For Proposed Acquisition Of Patheon

Tender Offer Scheduled to Expire at 5:00 p.m., New York City Time, on August 28, 2017

Jim Cramer: Agilent Technology Has Been One of My Favorites

Jim Cramer: Agilent Technology Has Been One of My Favorites

What's next for shares of Agilent Technology.

Secondaries Get Primary Attention; Discerning Market -- Cramer's Top Thoughts

Secondaries Get Primary Attention; Discerning Market -- Cramer's Top Thoughts

Cramer examines how the secondaries are getting some primary attention and also observes that the market is becoming more discerning.

Cramer: Secondary Offerings Get Primary Attention

Cramer: Secondary Offerings Get Primary Attention

Thermo Fisher and McCormick deals show the true colors of stocks.

TheStreet Quant Rating: A (Buy)